Abstract
The administration of antibiotics by the inhaled route is a widely recognized treatment in patients with cystic fibrosis (CF) and bronchiectasis. Tobramycin solution for inhalation (TOBI) has been available for many years and is licensed in the USA and Europe. While strong data support the use of aerosolized antibiotics for the treatment of respiratory infections in patients with CF or bronchiectasis, only a few clinical studies have examined the role of aerosolized antibiotics in the treatment of pneumonia, including ventilator-associated pneumonia (VAP) in these patients. During the last decade increasing interest has been directed towards alternative treatments to the systemic administration of antimicrobial agents for the treatment of patients with hospital-acquired pneumonia or VAP due to multidrug-resistant (MDR) Gram-negative bacteria. Recent publications demonstrate the clinical benefits from administering inhaled aminoglycosides or polymyxins in patients with hospitalacquired pneumonia or VAP. In addition to antibiotics, antifungals, and antivirals have been administered by inhalation to specific groups of critically ill patients. However, randomized controlled trials dealing with the administration of anti-infective agents via the respiratory tract are necessary in order to validate the efficacy, safety, advantages, and disadvantages of this therapeutic approach for the treatment of nosocomial pneumonia.
Article PDF
Similar content being viewed by others
References
Farber JE, Ross J: The use of aerosol penicillin and streptomycin in bronchopulmonary infection. Calif Med 1950; 73: 214–217.
Steinkamp G, Tümmler B, Gappa M, Albus A, Potel J, Döring G, von der Hardt H: Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989; 6: 91–98.
MacLusky IB, Gold R, Corey M, Levison H: Long term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989; 7: 42–48.
Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H: Placebo controlled double blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88–92.
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23–30.
Ratjen F, Döring G, Nikolaizik WH: Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Lancet 2001; 358: 983–984.
Moss RB: Long term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.
Hodson ME, Gallagher CG, Govan JR: A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20: 658–664.
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, Cystic Fibrosis Therapeutics Development Network Study Group: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841–849.
Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, Crookes B, Schulman CI: Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect (Larchmt) 2007; 8: 73–82.
Heinzl B, Eber E, Oberwaldner B, Haas G, Zach MS: Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002; 33: 32–37.
Griese M, Muller I, Reinhardt D: Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 2002; 7: 79–80.
Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monterforte M, Varela M, Tempone AK, O’Riordan T, Darowalla F, Richman P: Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008; 36: 2008–2013.
Ghannam DE, Rodriguez GH, Raad II, Safdar A: Inhaled aminoglycosides in cancer patients with ventilator-associated Gramnegative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 2009; 28: 253–259.
Falagas ME, Kasiakou SK: Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333–1341.
Katz E, Demain AL: The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions. Bacteriol Rev 1977; 35: 557–564.
Storm DR, Rosenthal KS, Swanson PE: Polymyxins and related peptide antibiotics. Annu Rev Biochem 1977; 46: 723–763.
Beveridge EG, Martin AJ: Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 1967; 29: 125–135.
Catchpole CR, Andrews JM, Brenwald N, Wise R: A reassessment of the in vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255–260.
Hancock RE, Chaple DS: Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317–1323.
Schindler M, Osborn MJ: Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979; 18: 4425–4430.
Galea AC, Reis AO, Jones RN: Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183–190.
Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J: Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004; 54: 1057–1061.
Pharmax Ltd: Colomycin package insert information. Colomycin 1.000.000 IU vial—colistin sulphomethate sodium. Pharmax Ltd, Bexley. 1998.
Pino G, Conterno G, Colongo PG: Clinical observations on the activity of aerosol colimycin and of endobronchial instillations of colimycin in patients with pulmonary suppurations. Minerva Med 1963; 54: 2117–2122.
Valerius NH, Koch C, Hoiby N: Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 1991; 338: 725–726.
Hoiby N, Frederiksen B, Pressler T: Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4: 49–54.
Michalopoulos A, Kasiakou S, Mastora Z, Rellos K, Kaposkekis M, Falagas ME: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug resistant Gram-negativebacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53–R59.
Kwa AL, Loh C, Low JJG, Kurup A, Tam VH: Nebulized colistin in the treatment of pneumonia due to multi drug resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754–757.
Berlana D, Llop JM, Fort E, Badia MB, Jodar R: Use of colistin in the treatment of multidrug-resistant Gram-negative infections. Am J Health Syst Pharm 2005; 62: 39–47.
Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME: Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Resp Med 2008; 102: 407–412.
Ratzen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57: 306–311.
Marschke G, Sarauw A: Polymyxin inhalation therapeutic hazard. Ann Intern Med 1971; 74: 144–145.
Pereira GH, Muller PR, Levin AS: Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58: 235–240.
Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Dainew C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL: Microbiology, safety and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pumonol 2006; 41: 656–665.
Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S: Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401–1408.
Monforte V, Roman A, Gavalda J, Lopez R, Pou L, Simo M, Aguade S, Soriano B, Bravo C, Morell F: Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571–1574.
Knechtel SA, Klepser ME: Safety of aerosolized amphotericin B. Expert Opin Drug Saf 2007; 6: 523–532.
Hirschel B, Lazzaria A, Chopard P, Opravil M, Furrer HJ, Ruttimann S, Vernazza P, Chave JP, Ancarani V: A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii. N Engl J Med 1991; 324: 1079–1083.
Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly W, He W, Phillips L, Craven D, Van der Horst C, Feinberg J: A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection: NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 693–699.
Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK: Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis 2002; 4: 66–74.
Metersky ML, Colt HG, Olson LK, Shanks TG: AIDS related spontaneous pneumothorax. Risk factors and treatment. Chest 1995; 108: 946–951.
Beck-Sague C, Dooley SW, Hutton MD, Otten G, Breeden A, Crawford JT, Pitchenik AE, Woodley C, Cauthen G, Jarvis WR: Hospital outbreak of multidrug resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV infected patients. JAMA 1992; 268: 1280–1286.
Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL, AZLI Phase II Study Group: A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008; 43: 47–58.
Sexauer WP, Fiel SB: Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med 2003; 24: 717–726.
Alothman G, Ho B, Alsaadi MM, Ho SL, O’Drowsky L, Allen EL, Coates L: Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127: 522–529.
Schultsz C, Meester HH, Kranenberg AM, Savelkoul PH, Boejen-Donkers LE, Kaiser AM, deBree R, Snow GB, Vanderbroucke-Grauls CJ: Ultrasonic nebulizers as a potential source of methicillin resistant Staphylococcus aureus causing an outbreak in a university tertiary care hospital. J Hosp Infect 2003; 55: 269–275.
Mendelman PM, Smith AL, Levy J: Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761–765.
Westerman EM, Heijerman HGM, Frijlink HW: Dry powder inhalation versus nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin Drug Deliv 2007; 4: 91–94.
Eisenberg J, Pepe M, Williams-Warren JA, Aerosolized Tobramycin Study Group: Comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997; 111: 955–963.
Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C: Novel tobramycin inhalation powdering cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007; 42: 307–313.
Hagerman JK, Hancock KE, Klepser ME: Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006; 3: 71–86.
Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT: Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am J Respir Crit Care Med 1999; 160: 1711–1716.
Fiel SB: Aerosolized antibiotics in cystic fibrosis: current and future trends. Expert Rev Respir Med 2008; 2: 479–487.
Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W: Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8: 1594–1604.
Touw DJ, Jacobs FA, Brimicombe RW: Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 184–187.
LiPuma JJ: Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001; 120 (3 Suppl): S118–S123.
Ioannidou E, Siempos II, Falagas ME: Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007; 60: 1216–1226.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michalopoulos, A., Papadakis, E. Inhaled Anti-infective Agents: Emphasis on Colistin. Infection 38, 81–88 (2010). https://doi.org/10.1007/s15010-009-9148-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-009-9148-6